Presentations included two overviews of prospective outcomes data and clinical evidence supporting use of the test in early-stage breast cancer patients with node-positive and node-negative disease. Data also included new results from the Surveillance, Epidemiology, and End Results (SEER) Registry program of the National Cancer Institute (NCI) analyzing outcomes and clinical utility of the Breast Recurrence Score™ (RS) in patients with high-grade tumors, and findings from a clinical evaluation of the Breast DCIS Score™ in patients with ductal carcinoma in situ (DCIS). "The clinical evidence generated by independent researchers and Genomic Health is paramount, highlighting the accuracy of Oncotype DX in predicting clinical outcomes and its unique value in providing physicians with critical genomic intelligence to enhance breast cancer treatment decisions and patient benefit," said Steven Shak, M.D., chief scientific officer, Genomic Health.

You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund investors like Carl Icahn and George […]